Hyperresponsiveness of neutrophils from gp 91phox deficient patients to lipopolysaccharide and serum amyloid A.
We demonstrate here that neutrophils from chronic granulomatous disease (CGD) patients release larger amounts of interleukin-8 (IL-8) and tumor necrosis factor alpha (TNF-alpha) than neutrophils from control subjects. Incremental cytokine production was observed under both basal and stimulated conditions in neutrophils from two CGD (gp 91phox) patients. The basal production of IL-8 was over seven-fold greater in CGD patients. The two samples assayed showed 3- and 10-fold increases in TNF-alpha. Basically, the same magnitude of increment was observed in lypopolysaccharide (LPS) and serum amyloid A protein (SAA)-stimulated cells. We also found that the levels of SAA and IL-8 were higher in the serum of CGD patients than the levels found in the serum of healthy donors. The increased responsiveness of neutrophils from CGD patients may be closely related with a deficiency in the assembly of the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase enzyme system, or it may be due to a frequent inflammatory condition in these patients. In the latter case, the increased serum levels of systemic inflammatory factors, among them SAA, would contribute to the sustained accumulation and activation of phagocytes. Whatever the origin, the excessive production of cytokines may lead to inappropriate activation and tissue injury and even to increased susceptibility to invasive microorganisms, impairing the quality life of CGD patients.
Hatanaka
Elaine
E
Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil. ehata@usp.br
Carvalho
Beatriz Tavares Costa
BT
Condino-Neto
Antônio
A
Campa
Ana
A
D000328:Adult; D002648:Child; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000201:enzymology* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis / Q000097:blood; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D008562:Membrane Glycoproteins / Q000172:deficiency* / Q000235:genetics; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases / Q000172:deficiency* / Q000235:genetics; D009504:Neutrophils / Q000737:chemistry / Q000187:drug effects / Q000276:immunology*; D000685:Serum Amyloid A Protein / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D016209:Interleukin-8; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; C056558:CYBB protein, human; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases